The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thank you Wigster77 for uploading the video of the question asked to JVT about the Synairgen treatment. His answer was very classy and matches his actions of the previous week . That is why he got to the top of his profession. When the Panorama documentary comes out later this year dedicated to the story of the development of the Synairgen wonder treatment, that video clip will be in the program.
Correct link now attached
https://www.pharmaceutical-technology.com/news/brii-biosciences-eua-us-fda-covid-19-combination/
https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials#activ2
EUA still not approved in USA
And the active comparator in ACTIV 2 Phase 3 is the neutralising antibody made by Regeneron that doesn't work on Omicron. Leaving 3 treatments only that are effective. These being GSK/VIR Sotrovimab, SAB 185 and SNG001 .
Topsharepicks. Put your £25k in Synairgen. Phase 3 clinical trial results of their inhaled inteferon beta 1a covid treatment will be announced any day. The results will be very good. Why else has the company advertised just yesterday multiple senior positions in USA when currently they have no staff there and only around 30 employees in total. Soon the whole world will know about this company. I have a big shareholding in Beowulf but my shareholding in Synairgen is 4 times larger. Enjoy the ride
https://www.bbc.co.uk/sounds/play/w3ct1l4w
Broadcast today at 9.30am. Includes an interview with VIR Technology researchers
14.5p in Sweden based on 12.35 SEK= £1
Discount of 14% on AIM with a buy price of 12.5p. When LKAB (or other) agree a takeover price the differential will vanish as UK holders will be paid the agreed SEK price converted to sterling.
https://www.riksdagen.se/sv/dokument-lagar/dokument/interpellationsdebatt/be****-om-kallak_H910191
The fact that Synairgen gets a special section of its own at the end of the Hardman report says it all. The author of this report has to display a cautious approach. If he was as excited about the potential as most of us are and it all goes pear-shaped then he will have more to worry about than his own personal investment. He has a career to worry about.
Canny investors can join the dots and if they hadn't heard of Synairgen before reading this Hardman report then they'll be doing their own research now.